Paradigm Biopharmaceuticals Limited is a late-stage drug development company engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). PPS is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans. It develops PPS under the brand name Zilosul. Other indications under investigation for PPS include the treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses; treating alphavirus-induced arthralgia; chronic heart failure; acute respiratory distress syndrome; and allergic respiratory conditions. It is also advancing early formulation development for Pentacoxib, an oral combination of PPS and a COX-2 inhibitor targeting patients with earlier-stage OA.

• Revenue in AUD (TTM)7.11m
• Net income in AUD-18.77m
• Incorporated2014
• Employees--

• Location
  Paradigm Biopharmaceuticals LtdLevel 15, 500 Collins StMELBOURNE 3000AustraliaAUS
• Phone+61 39629-5566
• Fax+61 39629-5466
• Websitehttps://paradigmbiopharma.com/